May 2nd 2024
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.
February 27th 2024
February 18th 2024
Early-Onset Gastric Cancer Suggested to be Genetically and Clinically Distinct
January 20th 2020Incidence of early-onset gastric cancer has steadily increased in the US, now comprising >30% of new gastric cancer cases today, causing researchers to try and discover what makes this disease type unique.
First-Line Ramucirumab Delays Progression in Gastric, Gastroesophageal Junction Adenocarcinoma
January 19th 2018First-line ramucirumab in combination with chemotherapy significantly improved progression-free survival in patients with metastatic gastric or gastroesophageal junction adenocarcinoma, according to results of the RAINFALL trial.
HIPEC Increased Survival in Gastric Cancer With Peritoneal Metastasis
January 19th 2018Undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) resulted in improved overall survival compared with resection alone for patients with gastric cancer with peritoneal carcinomatosis, according to data presented at the 2018 Gastrointestinal Cancers Symposium.
Olaparib/Paclitaxel Failed to Improve Survival in Advanced Gastric Cancer
November 28th 2017The combination of olaparib plus paclitaxel failed to significantly improve overall survival compared with placebo plus paclitaxel in Asian patients with advanced gastric cancer, according to the phase III results of the GOLD study.
Adjuvant Chemo Improved Survival in Gastroesophageal Cancer
October 2nd 2017Treatment with adjuvant chemotherapy improved the overall survival of locally advanced gastroesophageal adenocarcinoma in patients treated with preoperative chemoradiotherapy and resection, according to the results of an analysis of the National Cancer Database.
Updated Results Show Continued Pembrolizumab Activity in Gastric Cancer
September 11th 2017Updated results from the KEYNOTE 059 phase II trial showed that pembrolizumab alone or in combination with chemotherapy has promising antitumor activity for patients with advanced gastric or gastroesophageal junction cancer.
Novel Agent S-1 Has Similar Efficacy to 5-FU in Certain Gastric Cancers
August 10th 2017Results of a phase III trial suggest that the combination of the contemporary oral fluoropyrimidine S-1 and cisplatin offers similar efficacy to 5-flourouracil and cisplatin in patients with chemotherapy-naive diffuse type adenocarcinoma of the gastroesophageal junction or stomach.